Animal subspecies B189 of Bifidobacterium animalis and its applications

By using the acid- and bile-resistant Bifidobacterium animalis subspecies B189 strain, the problem of probiotic inactivation in the gastric environment was solved, achieving effective inhibition of Helicobacter pylori, improving gastric flora, and reducing the risk of gastric cancer.

CN122326475APending Publication Date: 2026-07-03HUOJIA TIANZHONG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HUOJIA TIANZHONG BIOTECHNOLOGY CO LTD
Filing Date
2026-05-13
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

When probiotics enter the stomach, they lose their activity due to the bile and gastric acid environment, and cannot effectively inhibit Helicobacter pylori, leading to gastric flora imbalance and increasing the risk of metachronous gastric cancer.

Method used

Bifidobacterium animalis subspecies B189 was used, which has acid and bile resistance, to develop a probiotic preparation that inhibits Helicobacter pylori.

Benefits of technology

Bifidobacterium animalis subspecies B189 remains active under extreme conditions, significantly inhibits the growth of Helicobacter pylori, improves gastric flora imbalance, and reduces the risk of gastric cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention relates to the field of biomedical technology, specifically to a subspecies of Bifidobacterium animalis B189 and its applications. The classification name of this strain is... Bifidobacterium animalum subsp . animal The accession number is CGMCC No. 37052. Bifidobacterium animalis B189 not only exhibits significant antibacterial effects against Helicobacter pylori, but also possesses extremely strong acid and bile resistance, making it valuable for the development of microbial agents to inhibit Helicobacter pylori.
Need to check novelty before this filing date? Find Prior Art